Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Dasatinib
Related studies linked through entity extraction aliases.
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Solid Tumors Using Ixabepilone and Dasatinib
- Status
- COMPLETED
- Phase
- PHASE1
Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
- Status
- COMPLETED
- Phase
- NA
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
- Status
- COMPLETED
- Phase
- PHASE1
Dasatinib in Resectable Malignant Pleural Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE1
Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts
- Status
- COMPLETED
- Phase
- NA
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
- Status
- COMPLETED
- Phase
- PHASE1
A Phase I/Expansion Study of Dasatinib
- Status
- TERMINATED
- Phase
- PHASE1
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
- Status
- COMPLETED
- Phase
- PHASE2
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2